Zentalis Pharmaceuticals (ZNTL) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Strategic priorities and trial focus

• Strategy centers on rapid development of azenosertib for platinum-resistant ovarian cancer with high cyclin E1 expression, prioritizing the DENALI registration trial and the ASPENOVA confirmatory Phase 3 trial.

• DENALI Part 2 is enrolling, with dose selection between 300 mg and 400 mg ongoing; final dose selection and trial readout expected by year-end 2026.

• ASPENOVA Phase 3 trial mirrors DENALI eligibility, is randomized against standard-of-care, and includes an adaptive dose confirmation arm to accelerate timelines.

• Biomarker-driven patient selection uses a validated IHC assay for cyclin E1, with about 50% of eligible patients expected to be positive.

• Prioritization remains on ovarian cancer, with other indications or combinations considered secondary and dependent on resource availability.

Clinical profile and differentiation

• Azenosertib is an oral, non-chemo option, offering a differentiated profile from ADCs and chemotherapy, targeting a specific biomarker-defined population.

• Demonstrates a favorable tolerability and safety profile, with low rates of high-grade neutropenia and manageable GI side effects.

• Data-driven clinical oversight and proactive site support are used to optimize safety and management during trials.

• Dose selection is based on overall risk-benefit, response rate, and PKPD modeling, with both doses showing similar tolerability.

• Efficacy bar for accelerated approval is around 30% ORR and 5–6 months duration of response, with current data exceeding these thresholds.

Trial design and regulatory strategy

• DENALI is a single-arm trial for accelerated approval, while ASPENOVA is a randomized controlled trial, both using the same biomarker criteria.

• Adaptive design in ASPENOVA allows for rapid initiation and dose confirmation, minimizing delays between trials.

• Regulatory engagement has aligned trial designs with FDA preferences, supporting a clear path for both accelerated and full approval.

• Changes in eligibility criteria between DENALI parts include prospective biomarker selection and limits on prior lines of therapy.

• Cross-trial evidence suggests cyclin E high expressors have poorer prognosis, supporting the need for targeted therapy.